An AI-Designed Cancer Vaccine Hit a 75% Response in Melanoma

Evaxion's EVX-01, a personalized peptide vaccine designed entirely by its AI-Immunology platform, achieved a 75% objective response rate in 16 patients with advanced melanoma treated with pembrolizumab, with responders still in remission at three years. The AI's top-ranked neoantigens were the ones that triggered the strongest immune reactions. The trial is small and open-label, with no placebo arm.